RA
ABVX

Rosalind Advisors’s Abivax ABVX Stock Holding History

Rosalind Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-139,983
Closed -$1.61M – 41
2024
Q3 		$1.61M Sell
139,983
-238,433
-63% -$2.86M 1.03% 21
2024
Q2 		$5M Hold
378,416
– – 3.85% 11
2024
Q1 		$5.41M Buy
+378,416
New +$4.88M 5.06% 8

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Rosalind Advisors's ABVX Position: Q4 2024 in Review

Rosalind Advisors sold out of Abivax (ABVX) in Q4 2024, closing a stake of 139,983 shares — an estimated $1.61M sold.

Rosalind Advisors first reported a position in ABVX in Q1 2024 and held it in 3 quarters. The position peaked at $5.41M in Q1 2024. 48 funds tracked by Wall St. Rank hold ABVX as of Q4 2024.

  • Rosalind Advisors reported no remaining Abivax position as of Q4 2024 after selling out during the quarter.
  • Rosalind Advisors sold 139,983 Abivax shares in Q4 2024, an estimated $1.61M.
  • Rosalind Advisors first reported a position in Abivax in Q1 2024 and held it in 3 quarters.
  • Rosalind Advisors's Abivax position peaked at $5.41M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Abivax as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.